Sudarshan Pharma Industries Q4 FY26: Revenue ₹220.92 Cr, EBITDA margin 9.14%
Q4 FY26 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹221Cr
- +36.7% YoY
- +31.5% QoQ
- Net profit
- ₹11Cr
- +53.8% YoY
- +174.7% QoQ
- Margin
- 9.14%
- −0.7 pp YoY
- +2.7 pp QoQ
Top 10 Chemicals & Petrochemicals companies on management guidance
See the sector's top 10 — free with your mobile number.
Sudarshan Pharma Industries Ltd Q4 FY26 key numbers
- Revenue
- Revenue from Operations for Q4 March 2026: ₹220.92 Cr.
As stated in Sudarshan Pharma Industries Ltd's Q4 FY26 investor presentation · published 25 Sept 2026. Reported figures, not investment advice.
Based on Sudarshan Pharma Industries Ltd's Q4 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Revenue from Operations for Q4 March 2026: ₹220.92 Cr (Page 41) - Revenue from Operations for Q4 March 2025: ₹168.01 Cr (quarter ended Dec 2025, closest quarterly prior data) - Year-on-year growth inf Quarterly EBITDA (Q4 March 2026): INR 20.19 Cr with an EBITDA margin of 9.14%.
From Sudarshan Pharma Industries Ltd's Q4 FY26 earnings-call transcript · updated 25 Sept 2026.
Revenue & Sales Performance
- Revenue from Operations for Q4 March 2026: ₹220.92 Cr (Page 41)
- Revenue from Operations for Q4 March 2025: ₹168.01 Cr (quarter ended Dec 2025, closest quarterly prior data)
- Year-on-year growth inferred for Q4 Mar 2026 vs Mar 2025 is approximately 31.4% (₹220.92 Cr vs ₹168.01 Cr)
- FY 2026 Revenue from Operations: ₹703.06 Cr vs FY 2025 ₹505.05 Cr, a 39.2% increase (Page 42)
- Outlook for FY 26-27 export turnover target: Minimum ₹100 Cr (Page 13)
2 more points from Sudarshan Pharma Industries Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Sudarshan Pharma Industries Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Nutraceuticals Plant project: Rs. 2.5 Cr. project cost with Rs. 1.15 Cr. machinery cost (2019-2020).
- Oral liquid and capsule manufacturing unit erected at Palghar (2021-2022).
- Vitamin B1 and B6 manufacturing under Production Linked Incentive (PLI) schemes; new products developed and to be first made in India (2021-2022).
- New unit development in Palghar (2023-2024).
- Acquisitions: Ratna Lifesciences & 51% of Ishwari Healthcare (2024-2025).
- Proposed allotment of FCCB worth 20 Million USD (2025-2026).
2 more points from Sudarshan Pharma Industries Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Sudarshan Pharma Industries Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Sudarshan Pharma Industries Ltd said on order book & pipeline — free account, 30 seconds.
Sudarshan Pharma Industries Ltd — Quarterly revenue & net profit
Sudarshan Pharma Industries Ltd Q4 FY26 results — key figures
| ₹ Cr | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 221 | 162 | +36.7% | 168 | +31.5% |
| Operating profit (EBITDA) | 20 | 16 | +26.8% | 11 | +85.8% |
| Operating margin | 9.14% | 9.86% | -0.7 pp | 6.47% | +2.7 pp |
| Profit before tax | 16 | 10 | +58.8% | 5 | +202.1% |
| Net profit (PAT) | 11 | 7 | +53.8% | 4 | +174.7% |
| EPS (₹) | 0.45 | 0.31 | +45.2% | 0.18 | +150% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹217 Cr, net profit ₹8 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Sudarshan Pharma's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Indian Phosphate (Q4 FY26)
H2 FY26 Revenue (Consolidated):** ₹580.25 Cr, up from ₹451.59 Cr in H2 FY25 — a year-on-year increase of ₹128.66 Cr. Key investor presentation takeaways from In
- Paragon Fine (Q4 FY26)
Revenue for H2FY26:** Rs 68.88 Cr, up 7.41% YoY from Rs 64.13 Cr in H2FY25 (Page 22). Key investor presentation takeaways from Paragon Fine's Q4 FY26 investor p
- IVP (Q4 FY26)
Q4 FY26 revenue from operations: ₹164.44 crore . Key investor presentation takeaways from IVP's Q4 FY26 investor presentation — and how it ranks against sector
- Vishnu Chemicals (Q4 FY26)
Q4 FY26 Operating Revenues: ₹450.3 crore, up 14.7% YoY from ₹392.6 crore in Q4 FY25 (Page 5). Key investor presentation takeaways from Vishnu Chemicals Ltd's Q4
Potential multibaggers · Q2 FY27
Potential multibaggers in Chemicals & Petrochemicals
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Sudarshan Pharma Industries Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Sudarshan Pharma Industries Ltd Q4 FY26 results?
Revenue from Operations for Q4 March 2026: ₹220.92 Cr (Page 41) - Revenue from Operations for Q4 March 2025: ₹168.01 Cr (quarter ended Dec 2025, closest quarterly prior data) - Year-on-year growth inf Quarterly EBITDA (Q4 March 2026): INR 20.19 Cr with an EBITDA margin of 9.14%.
What is Sudarshan Pharma Industries Ltd share price analysis?
Sudarshan Pharma Industries Ltd currently shows a neutral. The stock trades at a P/E of 39.4 with a market cap of ₹990 Cr. Investors should review the full earnings analysis for detailed insights.
Is Sudarshan Pharma Industries Ltd planning capital expenditure?
Nutraceuticals Plant project: Rs. 2.5 Cr. project cost with Rs. 1.15 Cr. machinery cost (2019-2020).
Keep Sudarshan Pharma Industries Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
